Innate Pharma names Mondher Mahjoubi as chairman of executive board
Dr. Mahjoubi is currently Senior Vice President, Therapeutic Area Head-Oncology, Global Product and Portfolio Strategy, at AstraZeneca. He has been instrumental in driving the oncology strategy at AstraZeneca and beforehand at Genentech.
Dr. Mahjoubi is a medical oncologist trained at Institut Gustave Roussy (Paris-Villejuif).
He is bringing more than 20 years of experience working in clinical development, marketing and strategy in Europe and the USA for leading pharmaceutical companies in the field of oncology such as Aventis, Sanofi, Roche-Genentech, and AstraZeneca.
Dr. Brailly, who co-founded Innate Pharma 17 years ago, joins the Supervisory Board and will become its Chairman, succeeding Gilles Brisson who is stepping down after nine years in that position, and remains on the Board.
Dr. Philippe Pouletty, the longest serving member of the Board, will resign from the Board.
As part of the governance changes, Laure-Hélène Mercier has been appointed as Chief Financial Officer.
Ms. Mercier was previously EVP, Finance, in charge of financial operations and, before that, Head of Investor Relations.
Catherine Moukheibir, who has played a critical role as Senior Advisor for financial strategy, is leaving the Executive Board but will maintain her close links with the Company in an advisory position.
The leadership team and board changes will take effect on December 30th, 2016.